Oncology Corporate Profile
Acetylon Pharmaceuticals, Inc., based in Boston, Massachusetts, is a leader in the development of novel small molecule drugs targeting epigenetic mechanisms for the enhancement of therapeutic outcomes in cancer and other critical human diseases. The Company_†_s epigenetic drug discovery platform has yielded a proprietary portfolio of optimized, orally-administered Class I and Class II histone deacetylase (HDAC) selective compounds. Alteration of HDAC regulation through selective HDAC inhibition is thought to be applicable to a broad range of diseases including cancer, sickle cell disease and beta-thalassemia, and autoimmune and neurodegenerative diseases. Acetylon_†_s lead drug candidate, ricolinostat (ACY-1215), is a selective HDAC6 inhibitor currently in Phase 1b clinical development for the treatment of multiple myeloma.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|Acy-1215 + pomalidomide)||histone deacetylase (HDAC) inhibitor||Multiple Myeloma||II||Celgene|
|Acy-1215||histone deacetylase (HDAC) inhibitor||Multiple Myeloma||II||Celgene|
|Acy-1215 (+ bortezomib and dexamethasone)||histone deacetylase (HDAC) inhibitor||Multiple Myeloma||I||Celgene|
|Acy-1215 (+ lenalidomide and dexamethasone)||histone deacetylase (HDAC) inhibitor||Multiple Myeloma||I||Celgene|